Previous close | 238.26 |
Open | 236.28 |
Bid | 234.19 x 200 |
Ask | 234.83 x 200 |
Day's range | 233.31 - 237.71 |
52-week range | 204.44 - 261.54 |
Volume | |
Avg. volume | 481,744 |
Market cap | 10.396B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 11.83 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
United Therapeutics (UTHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.